Jun. 3 at 5:08 PM
The
$CRBU /
$PFE Countdown: Everything Converges in June
• June 11
$CRBU : EHA embargo lifts.
CB-011 received an Oral Presentation at EHA 2026 — one of the most selective and visible formats at a leading global hematology conference.
(Chosen by the Scientific Program Committee after review of the submitted data.)
For me, that's the key catalyst.
The market cap currently implies very little value for CB-011's potential as an off-the-shelf BCMA CAR-T platform.
Then there's the interesting timing:
• June 29: Pfizer's ROFN and information-rights agreement expire.
Remember:
$PFE invested
$25M in
$CRBU in 2023, secured ROFN rights around CB-011-related assets, obtained information rights, and placed its Multiple Myeloma development head, Sriram Krishnaswami, PhD, on Caribou's Scientific Advisory Board.
Maybe the timing means nothing.
Maybe EHA is simply major public validation event before Pfizer decides whether the program is strategically interesting.
